Intralesional Diode Laser Treatment of Fistulas in Hidradenitis Suppurativa
NCT ID: NCT04508374
Last Updated: 2021-08-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
20 participants
INTERVENTIONAL
2020-12-10
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Creams, tablets, and injections aim to gain disease control, yet are sometimes not sufficient. Once HS tunnels have formed, surgical intervention is often required.
Recently, emergence of flexible diode laser fibers has enabled treatment of tunnels from within. The technique has been tested for perianal tunnels and in few studies also for HS tunnels with promising results. Overall, the laser fiber technique is still new, and knowledge of optimal treatment settings is sparse. However, there is reason to believe that intralesional laser fiber treatment of HS tunnels may provide a new tissue-sparing alternative to conventional surgical techniques with a potential to produce fewer side effects, less scaring, shorter downtime after surgery and possibly, also improved inflammatory control.
This study aims to investigate the efficacy and safety of laser fiber treatment of HS tunnels.
Method The project is carried out at the Dermatological Department, Roskilde University Hospital under the leadership of principal investigator Professor DmSc Gregor Jemec.
A prospective cohort study of intralesional laser fiber treatment of HS fistulas is planned.
After signing informed consent, patients with two comparable HS tunnels in typical areas will draw lot to receive experimental laser fiber treatment of one tunnel while the other tunnel serve as control. Efficacy will be monitored by pain scores, ultrasound, clinical photos, clinical measures of disease activity, quality-of-life scores, and skin biopsies. Patients will be followed 2, 6, 12 weeks and if possible, also 52 weeks after treatment. After 12 weeks, patients will be offered laser fiber treatment or standard of care surgery to the untreated control tunnel.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Compare Two Treatments for Axillary Hidradenitis Suppurativa: Carbon Dioxide Laser Versus Surgical Deroofing
NCT02163746
Safety and Treatment of Cryoinsufflation in Treatment of Hidradenitis Suppurativa
NCT05830149
Perforator Flaps for Axillary Hidradenitis Suppurativa
NCT03784313
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
NCT07244263
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
NCT06956235
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Hidradenitis suppurativa (HS) is a common chronic skin disease that manifests by intermittent flare-ups of inflamed painful nodules that often leave mutilating scars, chronic suppurating tunnels and a changed microbiome compared to normal skin. Symptoms typically begin during adolescence and patients struggle with pain, pruritus, malodor and purulent discharge compromising work life, physical exercise, and sexual habits. Consequently, the risk of social exclusion, anxiety, depression and suicide is increased among patients suffering from HS.
Topical and systemic medical treatments, e.g. in the form of antibiotics, vitamin A derivates, immune-modulatory drugs or biological therapies aim to control inflammation. Once fistulas have formed, surgical intervention is often required. Present surgical therapies comprise surgical deroofing where the fistulas are cut open and left to heal, removal of specific pathological structures by ablative laser surgery or complete surgical removal en bloc of affected HS skin followed by skin grafting.
Recently, emergence of flexible diode laser fibers has enabled intra-lesional laser treatments of fistulas and the technique has been applied for e.g. perianal fistulas. Two prospective and one retrospective cohort studies evaluated a total of 265 patients treated with 1470 nm laser fiber surgery for perianal fistulas, demonstrating primary healing with absence of symptoms after one treatment in 40% to 71% of patients, a median healing time of 5 weeks, and long-term closure beyond 12 months in 71% of patients6. Intralesional laser fiber treatment has also been tested in HS tunnels. One study of concomitant 630 nm laser fiber treatment and photodynamic therapy has demonstrated a significant reduction in hidradenitis severity score and complete response in 47 % of patients after one treatment session.
Intralesional flexible laser fibers have also been tested in the treatment of HS tunnels without concomitant photodynamic therapy. One study investigated four sessions of 1064 nm intralesional diode laser therapy performed in local anesthesia. In a total of 20 patients, a significant reduction of Sartorius score and improved quality of life was demonstrated. No patients experienced neither worsening of disease nor complete cure and adverse effects were mild and transient. It was proposed, that intralesional laser treatment may elicit a decontaminating as well as an denaturing effect. Histological evaluation of endo-venous 1470 nm laser fiber treatment have demonstrated uniform coagulation without carbonization. Overall, the intralesional laser fiber technique is still new, and knowledge of optimal laser wave lengths, energy levels, number of treatments and treatment intervals is sparse. In addition, little is known about laser-tissue interactions in vivo as well as in vitro. However, there is reason to believe that intralesional laser fiber treatment of HS tunnels may provide a new tissue-sparing alternative to conventional surgical techniques with a potential to produce fewer side effects, less scaring, shorter downtime after surgery and possibly, also improved inflammatory control.
This study aims to investigate the efficacy and safety of 1470 nm laser fiber treatment of HS tunnels and add new knowledge of the microbiota as well as of laser-tissue interactions by in vivo ultrasound and in vitro histology.
Methods:
Study execution:
The project will be carried out at the Dermatological Department, Roskilde University Hospital under the leadership of principal investigator Professor Gregor Jemec, MD, DMSc. Senior doctor Ditte Marie Lindhardt Saunte, MD, PhD and Medical Doctor Elisabeth Hjardem Taudorf MD, PhD will run the project in cooperation with the established research group at the department
Study design:
A prospective cohort study of intralesional laser fiber treatment of HS fistulas is planned. Demographic data and information regarding prior treatments for HS will be collected in standardized case-report forms.
After signing informed consent, patients with HS tunnels in typical areas will be enrolled. Patients who have at least two suitable tunnels in typical HS areas will be invited to participate in the randomised within-person design to receive experimental laser fibre treatment. Two comparable HS tunnels from each patient will be selected enabling a subsequent randomisation to receive treatment or to serve as an intra-individual control, respectively.
Intervention:
The experimental treatment consists of one session of thermal coagulation with intralesional 1470 nm diode laser fibre in the entire length of one HS tunnel after injection of local anaesthetics (Mepivacaine-adrenaline). Both ends of tunnels selected for laser treatment must be accessible from the skin surface to ensure treatment of the entire tunnel.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1470 nm diode laser treatment of right HS-fistula
This is an intra-person study, comparing outcomes within participants. All participants will receive active 1470 nm intra-lesional diode laser treatment on one HS tunnel. Half of the enroled patients will receive active treatment of the right side, while the HS tunnel on the left side will be left as an untreated control.
1470 nm intra-lesional diode laser treatment of right HS tunnel
Ten patients: 1470 nm intra-lesional diode laser treatment of right HS-tunnel randomized to active treatment.
1470 nm diode laser treatment of left HS-fistula
This is an intra-person study, comparing outcomes within participants. All participants will receive active 1470 nm intra-lesional diode laser treatment on one HS tunnel. Half of the enroled patients will receive active treatment of the left side, while the HS tunnel on the right side will be left as an untreated control.
1470 nm intra-lesional diode laser treatment of left HS tunnel
Ten patients: 1470 nm intra-lesional diode laser treatment of left HS-tunnel randomized to active treatment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
1470 nm intra-lesional diode laser treatment of right HS tunnel
Ten patients: 1470 nm intra-lesional diode laser treatment of right HS-tunnel randomized to active treatment.
1470 nm intra-lesional diode laser treatment of left HS tunnel
Ten patients: 1470 nm intra-lesional diode laser treatment of left HS-tunnel randomized to active treatment.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* aged 18 years or older
* Two appropriate HS fistulas
Exclusion Criteria
* Allergy to lidocaine or adrenaline
* Fragile physical health that cannot tolerate standard of care HS rescue therapy
* Pregnant or lactating women
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zealand University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gregor Jemec
Professor, PhD, DmsC, Head of Dpt.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gregor BE Jemec, DmSc, Prof.
Role: PRINCIPAL_INVESTIGATOR
Zealand University Hospital - Roskilde
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
zealand University Hospital Roskilde
Roskilde, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Saunte DML, Jemec GBE. Hidradenitis Suppurativa: Advances in Diagnosis and Treatment. JAMA. 2017 Nov 28;318(20):2019-2032. doi: 10.1001/jama.2017.16691.
Ring HC, Thorsen J, Saunte DM, Lilje B, Bay L, Riis PT, Larsen N, Andersen LO, Nielsen HV, Miller IM, Bjarnsholt T, Fuursted K, Jemec GB. The Follicular Skin Microbiome in Patients With Hidradenitis Suppurativa and Healthy Controls. JAMA Dermatol. 2017 Sep 1;153(9):897-905. doi: 10.1001/jamadermatol.2017.0904.
Thorlacius L, Cohen AD, Gislason GH, Jemec GBE, Egeberg A. Increased Suicide Risk in Patients with Hidradenitis Suppurativa. J Invest Dermatol. 2018 Jan;138(1):52-57. doi: 10.1016/j.jid.2017.09.008. Epub 2017 Sep 20.
Terzi MC, Agalar C, Habip S, Canda AE, Arslan NC, Obuz F. Closing Perianal Fistulas Using a Laser: Long-Term Results in 103 Patients. Dis Colon Rectum. 2018 May;61(5):599-603. doi: 10.1097/DCR.0000000000001038.
Wilhelm A, Fiebig A, Krawczak M. Five years of experience with the FiLaC laser for fistula-in-ano management: long-term follow-up from a single institution. Tech Coloproctol. 2017 Apr;21(4):269-276. doi: 10.1007/s10151-017-1599-7. Epub 2017 Mar 7.
Giamundo P, Esercizio L, Geraci M, Tibaldi L, Valente M. Fistula-tract Laser Closure (FiLaC): long-term results and new operative strategies. Tech Coloproctol. 2015 Aug;19(8):449-53. doi: 10.1007/s10151-015-1282-9. Epub 2015 Feb 28.
Suarez Valladares MJ, Eiris Salvado N, Rodriguez Prieto MA. Treatment of hidradenitis suppurativa with intralesional photodynamic therapy with 5-aminolevulinic acid and 630nm laser beam. J Dermatol Sci. 2017 Mar;85(3):241-246. doi: 10.1016/j.jdermsci.2016.12.014. Epub 2016 Dec 19.
Fabbrocini G, Franca K, Lotti T, Marasca C, Annunziata MC, Cacciapuoti S, Masara A, Romanelli M, Lotti J, Wollina U, Tchernev G, Zerbinati N. Intralesional Diode Laser 1064 nm for the Treatment of Hidradenitis Suppurativa: A Report of Twenty Patients. Open Access Maced J Med Sci. 2018 Jan 7;6(1):31-34. doi: 10.3889/oamjms.2018.045. eCollection 2018 Jan 25.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
19- 001165
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.